TY - JOUR
T1 - Missense variant contribution to USP9X-female syndrome
AU - Jolly, Lachlan A.
AU - Parnell, Euan
AU - Gardner, Alison E.
AU - Corbett, Mark A.
AU - Pérez-Jurado, Luis A.
AU - Shaw, Marie
AU - Lesca, Gaetan
AU - Keegan, Catherine
AU - Schneider, Michael C.
AU - Griffin, Emily
AU - Maier, Felicitas
AU - Kiss, Courtney
AU - Guerin, Andrea
AU - Crosby, Kathleen
AU - Rosenbaum, Kenneth
AU - Tanpaiboon, Pranoot
AU - Whalen, Sandra
AU - Keren, Boris
AU - McCarrier, Julie
AU - Basel, Donald
AU - Sadedin, Simon
AU - White, Susan M.
AU - Delatycki, Martin B.
AU - Kleefstra, Tjitske
AU - Küry, Sébastien
AU - Brusco, Alfredo
AU - Sukarova-Angelovska, Elena
AU - Trajkova, Slavica
AU - Yoon, Sehoun
AU - Wood, Stephen A.
AU - Piper, Michael
AU - Penzes, Peter
AU - Gecz, Jozef
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12
Y1 - 2020/12
N2 - USP9X is an X-chromosome gene that escapes X-inactivation. Loss or compromised function of USP9X leads to neurodevelopmental disorders in males and females. While males are impacted primarily by hemizygous partial loss-of-function missense variants, in females de novo heterozygous complete loss-of-function mutations predominate, and give rise to the clinically recognisable USP9X-female syndrome. Here we provide evidence of the contribution of USP9X missense and small in-frame deletion variants in USP9X-female syndrome also. We scrutinise the pathogenicity of eleven such variants, ten of which were novel. Combined application of variant prediction algorithms, protein structure modelling, and assessment under clinically relevant guidelines universally support their pathogenicity. The core phenotype of this cohort overlapped with previous descriptions of USP9X-female syndrome, but exposed heightened variability. Aggregate phenotypic information of 35 currently known females with predicted pathogenic variation in USP9X reaffirms the clinically recognisable USP9X-female syndrome, and highlights major differences when compared to USP9X-male associated neurodevelopmental disorders.
AB - USP9X is an X-chromosome gene that escapes X-inactivation. Loss or compromised function of USP9X leads to neurodevelopmental disorders in males and females. While males are impacted primarily by hemizygous partial loss-of-function missense variants, in females de novo heterozygous complete loss-of-function mutations predominate, and give rise to the clinically recognisable USP9X-female syndrome. Here we provide evidence of the contribution of USP9X missense and small in-frame deletion variants in USP9X-female syndrome also. We scrutinise the pathogenicity of eleven such variants, ten of which were novel. Combined application of variant prediction algorithms, protein structure modelling, and assessment under clinically relevant guidelines universally support their pathogenicity. The core phenotype of this cohort overlapped with previous descriptions of USP9X-female syndrome, but exposed heightened variability. Aggregate phenotypic information of 35 currently known females with predicted pathogenic variation in USP9X reaffirms the clinically recognisable USP9X-female syndrome, and highlights major differences when compared to USP9X-male associated neurodevelopmental disorders.
UR - http://www.scopus.com/inward/record.url?scp=85097438993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097438993&partnerID=8YFLogxK
U2 - 10.1038/s41525-020-00162-9
DO - 10.1038/s41525-020-00162-9
M3 - Article
C2 - 33298948
AN - SCOPUS:85097438993
SN - 2056-7944
VL - 5
JO - npj Genomic Medicine
JF - npj Genomic Medicine
IS - 1
M1 - 53
ER -